{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:44:04Z","timestamp":1792003444978,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81760032"],"award-info":[{"award-number":["81760032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pediatr-neonatol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics & Neonatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.pedneo.2022.05.020","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:16:07Z","timestamp":1674702967000},"page":"435-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia"],"prefix":"10.1016","volume":"64","author":[{"given":"Xiaoyan","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxiu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qulian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-3751","authenticated-orcid":false,"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedneo.2022.05.020_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib3","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","article-title":"Practical implications of the 2016 Revision of the World Health Organization Classification of lymphoid and myeloid neoplasms and acute leukemia","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2022.05.020_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cam4.969","article-title":"A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice","volume":"6","author":"Lin","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.pedneo.2022.05.020_bib5","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","article-title":"Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia","volume":"3","author":"Shiba","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.pedneo.2022.05.020_bib6","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.pedneo.2022.05.020_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pedneo.2022.05.020_bib8","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib9","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/leu.2015.181","article-title":"Mouse models for core binding factor leukemia","volume":"29","author":"Chin","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2022.05.020_bib11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.pedneo.2022.05.020_bib12","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib13","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","article-title":"Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML","volume":"115","author":"Pollard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib14","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pedneo.2022.05.020_bib15","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2003-07-2280","article-title":"A dominant-negative mutant of C\/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse","volume":"103","author":"Schwieger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/10428194.2018.1516876","article-title":"Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients","volume":"60","author":"Chen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pedneo.2022.05.020_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.pedneo.2022.05.020_bib18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ajh.23821","article-title":"Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy","volume":"89","author":"Solh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pedneo.2022.05.020_bib19","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr","year":"2018","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.pedneo.2022.05.020_bib20","first-page":"52","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.pedneo.2022.05.020_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pedneo.2022.05.020_bib22","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","article-title":"Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia","volume":"25","author":"Tarlock","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pedneo.2022.05.020_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/10428194.2017.1361025","article-title":"KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pedneo.2022.05.020_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exphem.2017.05.003","article-title":"D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia","volume":"52","author":"Omori","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pedneo.2022.05.020_bib25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pedneo.2022.05.020_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children\u2019s Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"}],"container-title":["Pediatrics & Neonatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957223000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875957223000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:57:31Z","timestamp":1761749851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875957223000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1875957223000190"],"URL":"https:\/\/doi.org\/10.1016\/j.pedneo.2022.05.020","relation":{},"ISSN":["1875-9572"],"issn-type":[{"value":"1875-9572","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pediatrics & Neonatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedneo.2022.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Taiwan Pediatric Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}